A Phase 3 interventional study of Bevacizumab and Capecitabine in Colorectal Cancer, sponsored by Hoffmann-La Roche. Completed at 10 sites in Turkey. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-08-08.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 230 studies testing bevacizumab in Colorectal Neoplasms — 49 open to participants now, 61 under way, 11 of them phase 3. Bevacizumab · Colorectal Neoplasms.
Among the 230 studies testing bevacizumab in Colorectal Neoplasms, this one is the 66th largest by enrollment of the 224 interventional ones that give a count, is one of 10 that started in 2008, is one of 42 in phase 3, and was the 61st registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →49 of the 230 studies testing bevacizumab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18–75
Gilead Sciences · Sites in United States, Australia, Korea, Republic of and 1 more country
Ages 18+
Fujian Cancer Hospital · Sites in China
Ages 18–75
EMD Serono Research & Development Institute, Inc. · Sites in United States, Argentina, Australia and 16 more countries
Ages 18+
Oncolytics Biotech · Sites in United States
Ages 18+
By country, each count listing its studies:
Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
230 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 37 · Phase 2 150 · Phase 3 48 · Phase 4 8
First in 2000; this study’s year is marked. 10 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 123 is above the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 63 across the 224 interventional studies. Of the 144 that completed or were terminated, 50 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 230 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
111 studies in Colorectal Neoplasms by Hoffmann-La Roche: 3 open now, 7 under way, none of them phase 3. Of 99 finished, 52 (53%) have results posted.
Among the 111 studies in Colorectal Neoplasms by Hoffmann-La Roche, this one is the 35th largest by enrollment of the 77 interventional ones that give a count, is one of 8 that started in 2008, is one of 15 in phase 3, and was the 25th registered.
Hoffmann-La Roche’s Colorectal Neoplasms studies by the year they started, since 1998.
14 of the studies testing bevacizumab in Colorectal Neoplasms that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03303495Phase 3Sun Yat-sen UniversityA Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC | 2026-12-31 |
| NCT06280495Phase 3Sun Yat-sen UniversityNeoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients | 2026-12-31 |
| NCT02997228Phase 3National Cancer Institute (NCI)Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study | 2027-06-01 |
| NCT07007728Peking University Cancer Hospital & InstituteIparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis | 2026-12-31 |
| NCT03401294University of SaskatchewanConversion From Unresectable To Resectable Metastatic Colorectal Cancer. | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 230 studies testing bevacizumab in Colorectal Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 111 in Colorectal Neoplasms:
This tab as a report to print or save as PDF → With an account.
This 2 arm study assessed the efficacy and safety of maintenance treatment with Avastin (bevacizumab) + Xeloda (capecitabine), after initial treatment with Xeloda + oxaliplatin + Avastin, in patients with metastatic colorectal cancer. Patients were randomized into one of 2 groups to receive 1) Xeloda + oxaliplatin + Avastin until disease progression or 2) Xeloda + oxaliplatin + Avastin for 6 3-week cycles, followed by Xeloda + Avastin until disease progression. Xeloda was administered at a dose of 1000 mg/m\^2 orally twice a day on days 1-14 of each cycle, oxaliplatin at a dose of 130 mg/m\^2 intravenously (iv) on day 1 of each cycle, and Avastin at a dose of 7.5 mg/kg iv on day 1 of each cycle.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received bevacizumab 7.5 mg/kg intravenously (IV) on Day 1 of each 3-week cycle + oxaliplatin 130 mg/m\^2 IV on Day 1 of each 3-week cycle + capecitabine 1000 mg/m\^2 orally twice a day on Days 1-14 of each 3-week cycle until disease progression.
Drug: Bevacizumab · Drug: Capecitabine · Drug: Oxaliplatin
Participants received bevacizumab 7.5 mg/kg intravenously (IV) on Day 1 of each 3-week cycle + oxaliplatin 130 mg/m\^2 IV on Day 1 of each 3-week cycle + capecitabine 1000 mg/m\^2 orally twice a day on Days 1-14 of each 3-week cycle for 6 cycles followed by bevacizumab 7.5 mg/kg intravenously (IV) on Day 1 of each 3-week cycle + capecitabine 1000 mg/m\^2 orally twice a day on Days 1-14 of each 3-week cycle until disease progression.
Drug: Bevacizumab · Drug: Capecitabine · Drug: Oxaliplatin
Bevacizumab was supplied as a solution in single-use vials.
Also known as: Avastin
Capecitabine was supplied as film-coated tablets.
Also known as: Xeloda
Oxaliplatin was supplied as a lyophilized powder in vials.
Also known as: Eloxatin
Progression-free Survival
Progression-free survival was defined as the time from the first administration of study drug to the first documented disease progression or death, whichever occurs first. Progressive disease was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the unequivocal progression of existing non-target lesions. All measurable lesions up to a maximum of 5 lesions per organ and 10 lesions in total, representative of all involved organs, should be identified as target lesions at Baseline. Target lesions should be selected on the basis of their size (lesions with the longest diameter) and their suitability for accurate repeated measurements (either by imaging techniques or clinically). A sum of the longest diameter for all target lesions will be calculated and reported as the Baseline sum longest diameter.
Time frame: Baseline to the end of the study (up to 4 years, 2 months)
Overall Survival
Overall survival was defined as the time from the first administration of study drug to death.
Time frame: Baseline to the end of the study (up to 4 years, 2 months)
Percentage of Participants With a Complete Response or a Partial Response
A complete response was defined as the disappearance of all target lesions. A partial response was defined as at least a 30% decrease in the sum of the longest diameter of target lesions taking as reference the Baseline sum longest diameter. All measurable lesions up to a maximum of 5 lesions per organ and 10 lesions in total, representative of all involved organs, should be identified as target lesions at Baseline. All other lesions (or sites of disease) should be identified as non-target lesions. Target lesions should be selected on the basis of their size (lesions with the longest diameter) and their suitability for accurate repeated measurements (either by imaging techniques or clinically). A sum of the longest diameter for all target lesions will be calculated and reported as the Baseline sum longest diameter.
Time frame: Baseline to the end of the study (up to 4 years, 2 months)
Time Until a Complete Response or a Partial Response
Time until a complete response or a partial response was defined as the time from the first administration of study drug until the first complete response or partial response.
Time frame: Baseline to Month 13
Duration of Response
Duration of response was defined as the time from the first complete response or partial response until disease progression or death. Progressive disease was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the unequivocal progression of existing non-target lesions. All measurable lesions up to a maximum of 5 lesions per organ and 10 lesions in total, representative of all involved organs, should be identified as target lesions at Baseline. Target lesions should be selected on the basis of their size (lesions with the longest diameter) and their suitability for accurate repeated measurements (either by imaging techniques or clinically). A sum of the longest diameter for all target lesions will be calculated and reported as the Baseline sum longest diameter.
Time frame: Baseline to the end of the study (up to 4 years, 2 months)
Percentage of Participants With Metastatic Lesions Previously Considered Inoperable Who Became Operable and Underwent Surgery
Time frame: Baseline to the end of the study (up to 4 years, 2 months)
Percentage of Participants With a R0 Resection
An R0 resection indicates a microscopically margin-negative resection, in which no gross or microscopic tumor remains in the primary tumor bed.
Time frame: Baseline to the end of the study (up to 4 years, 2 months)
| Milestone | Bevacizumab+Capecitabine+Oxaliplatin | Bevacizumab(B)+Capecitabine(C)+Oxaliplatin Followed by B+C |
|---|---|---|
| Started | 62 | 61 |
| Completed | 42 | 39 |
| Not completed | 20 | 22 |
| Withdrew: Adverse event | 9 | 6 |
| Withdrew: Death | 2 | 0 |
| Withdrew: Lack of efficacy | 3 | 7 |
| Withdrew: Lost to follow-up | 2 | 2 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Reason not specified | 3 | 6 |
Progression-free survival was defined as the time from the first administration of study drug to the first documented disease progression or death, whichever occurs first. Progressive disease was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the unequivocal progression of existing non-target lesions. All measurable lesions up to a maximum of 5 lesions per organ and 10 lesions in total, representative of all involved organs, should be identified as target lesions at Baseline. Target lesions should be selected on the basis of their size (lesions with the longest diameter) and their suitability for accurate repeated measurements (either by imaging techniques or clinically). A sum of the longest diameter for all target lesions will be calculated and reported as the Baseline sum longest diameter.
| Months | Bevacizumab+Capecitabine+Oxaliplatin | Bevacizumab(B)+Capecitabine(C)+Oxaliplatin Followed by B+C |
|---|---|---|
| Progression-free Survival | 9.0 ± 0.7 | 12.6 ± 1.0 |
Overall survival was defined as the time from the first administration of study drug to death.
| Months | Bevacizumab+Capecitabine+Oxaliplatin | Bevacizumab(B)+Capecitabine(C)+Oxaliplatin Followed by B+C |
|---|---|---|
| Overall Survival | 21.0 ± 1.3 | 25.4 ± 1.7 |
A complete response was defined as the disappearance of all target lesions. A partial response was defined as at least a 30% decrease in the sum of the longest diameter of target lesions taking as reference the Baseline sum longest diameter. All measurable lesions up to a maximum of 5 lesions per organ and 10 lesions in total, representative of all involved organs, should be identified as target lesions at Baseline. All other lesions (or sites of disease) should be identified as non-target lesions. Target lesions should be selected on the basis of their size (lesions with the longest diameter) and their suitability for accurate repeated measurements (either by imaging techniques or clinically). A sum of the longest diameter for all target lesions will be calculated and reported as the Baseline sum longest diameter.
| Percentage of participants | Bevacizumab+Capecitabine+Oxaliplatin | Bevacizumab(B)+Capecitabine(C)+Oxaliplatin Followed by B+C |
|---|---|---|
| Percentage of Participants With a Complete Response or a Partial Response | 53.2 | 59.0 |
Time until a complete response or a partial response was defined as the time from the first administration of study drug until the first complete response or partial response.
| Months | Bevacizumab+Capecitabine+Oxaliplatin | Bevacizumab(B)+Capecitabine(C)+Oxaliplatin Followed by B+C |
|---|---|---|
| Time Until a Complete Response or a Partial Response | 3.5 ± 2.8 | 2.9 ± 2.0 |
Duration of response was defined as the time from the first complete response or partial response until disease progression or death. Progressive disease was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the unequivocal progression of existing non-target lesions. All measurable lesions up to a maximum of 5 lesions per organ and 10 lesions in total, representative of all involved organs, should be identified as target lesions at Baseline. Target lesions should be selected on the basis of their size (lesions with the longest diameter) and their suitability for accurate repeated measurements (either by imaging techniques or clinically). A sum of the longest diameter for all target lesions will be calculated and reported as the Baseline sum longest diameter.
Results for this outcome have not been posted.
| Percentage of participants | Bevacizumab+Capecitabine+Oxaliplatin | Bevacizumab(B)+Capecitabine(C)+Oxaliplatin Followed by B+C |
|---|---|---|
| Percentage of Participants With Metastatic Lesions Previously Considered Inoperable Who Became Operable and Underwent Surgery | 58.1 | 54.1 |
An R0 resection indicates a microscopically margin-negative resection, in which no gross or microscopic tumor remains in the primary tumor bed.
Results for this outcome have not been posted.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bevacizumab+Capecitabine+Oxaliplatin | — | 12/62 (19.4%) | 62/62 (100%) |
| Bevacizumab(B)+Capecitabine(C)+Oxaliplatin Followed by B+C | — | 21/61 (34.4%) | 61/61 (100%) |
| Event | Bevacizumab+Capecitabine+Oxaliplatin | Bevacizumab(B)+Capecitabine(C)+Oxaliplatin Followed by B+C |
|---|---|---|
| Clinical worseningGeneral disorders | 0/62 | 2/61 |
| DiarrheaGastrointestinal disorders | 2/62 | 2/61 |
| Urinary tract infectionInfections and infestations | 1/62 | 2/61 |
| Abdominal painGastrointestinal disorders | 1/62 | 1/61 |
| Angina pectorisCardiac disorders | 0/62 | 1/61 |
| AnorexiaGastrointestinal disorders | 0/62 | 1/61 |
| BronchospasmRespiratory, thoracic and mediastinal disorders | 0/62 | 1/61 |
| Decreased breath sounds on right lower zoneRespiratory, thoracic and mediastinal disorders | 0/62 | 1/61 |
| Defence, distension and rigidity in abdomenGastrointestinal disorders | 0/62 | 1/61 |
| Difficulty in breathingRespiratory, thoracic and mediastinal disorders | 0/62 | 1/61 |
| Event | Bevacizumab+Capecitabine+Oxaliplatin | Bevacizumab(B)+Capecitabine(C)+Oxaliplatin Followed by B+C |
|---|---|---|
| NauseaGastrointestinal disorders | 27/62 | 17/61 |
| NeuropathyNervous system disorders | 25/62 | 25/61 |
| Hemifacial spasmVascular disorders | 23/62 | 24/61 |
| VomitingGastrointestinal disorders | 24/62 | 16/61 |
| WeaknessGeneral disorders | 24/62 | 18/61 |
| DiarrheaGastrointestinal disorders | 24/62 | 17/61 |
| AnorexiaGastrointestinal disorders | 17/62 | 13/61 |
Intent-to-treat population: All randomized participants with a least 1 post-randomization efficacy assessment.
| Age, Continuous(years) | Bevacizumab+Capecitabine+Oxaliplatin | Bevacizumab(B)+Capecitabine(C)+Oxaliplatin Followed by B+C | Total |
|---|---|---|---|
| Mean | 56.9 ± 11.2 | 57.6 ± 11.3 | 57.2 ± 11.2 |
| Sex: Female, Male(Participants) | Bevacizumab+Capecitabine+Oxaliplatin | Bevacizumab(B)+Capecitabine(C)+Oxaliplatin Followed by B+C | Total |
|---|---|---|---|
| Female | 23 | 23 | 46 |
| Male | 39 | 38 | 77 |
The record gives a start of Mar 2008, a primary completion of May 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2014, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bevacizumab · Capecitabine · Oxaliplatin